A shift in drug development from blockbuster drugs to medicines for specific patient populations and the role of drug discovery ventures
First written in FY2023-Q2. 4 of 5 entries say "Restated". Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1RestatedAnnual report
「Meanwhile, new drug development is shifting from so-called blockbuster medicines, which target many patients and are expected to generate large and stable future revenues, toward medicines that provide effective treatment for specific patient populations. Drug-discovery ventures, which concentrate resources in specific fields and make decisions quickly, are said to play a central role in this shift.」
新薬開発がブロックバスター中心から特定患者群向けへ移行し、創薬ベンチャーが中心的役割を担うとの業界認識を再掲している。 - FY2024-Q2RestatedAnnual report
「Meanwhile, new drug development is shifting from so-called blockbuster medicines, which target many patients and are expected to generate large and stable future revenues, toward medicines that provide effective treatment for specific patient populations. Drug-discovery ventures, which concentrate resources in specific fields and make decisions quickly, are said to play a central role in this shift.」
新薬開発がブロックバスター中心から特定患者群向けへ移行し、創薬ベンチャーが中心的役割を担うとの業界認識を再掲している。 - FY2024-Q1RestatedAnnual report
「Meanwhile, new drug development is shifting from so-called blockbuster medicines, which target many patients and are expected to generate large and stable future revenues, toward medicines that provide effective treatment for specific patient populations. Drug-discovery ventures, which concentrate resources in specific fields and make decisions quickly, are said to play a central role in this shift.」
新薬開発がブロックバスター中心から特定患者群向けへ移行し、創薬ベンチャーが中心的役割を担うとの業界認識を再掲している。 - FY2023-Q3RestatedAnnual report
「Meanwhile, new drug development is shifting from so-called blockbuster medicines, which target many patients and are expected to generate large and stable future revenues, toward medicines that provide effective treatment for specific patient populations. Drug-discovery ventures, which concentrate resources in specific fields and make decisions quickly, are said to play a central role in this shift.」
新薬開発がブロックバスター中心から特定患者群向けへ移行し、創薬ベンチャーが中心的役割を担うとの業界認識を再掲している。 - FY2023-Q2First statedAnnual report
「Meanwhile, new drug development is shifting from so-called blockbuster medicines, which target many patients and are expected to generate large and stable future revenues, toward medicines that provide effective treatment for specific patient populations. Drug-discovery ventures, which concentrate resources in specific fields and make decisions quickly, are said to play a central role in this shift.」
The company describes the industry view that new drug development is moving away from blockbuster medicines toward treatments for specific patient populations, with drug-discovery ventures playing a central role.